Matching articles for "glacanezumab"

In Brief: Hypertension with Erenumab (Aimovig)

   
The Medical Letter on Drugs and Therapeutics • April 5, 2021;  (Issue 1621)
The once-monthly, subcutaneously injected calcitonin gene-related peptide (CGRP) receptor antagonist erenumab-aooe (Aimovig) was approved by the FDA in 2018 for preventive treatment of migraine in adults....
The once-monthly, subcutaneously injected calcitonin gene-related peptide (CGRP) receptor antagonist erenumab-aooe (Aimovig) was approved by the FDA in 2018 for preventive treatment of migraine in adults. Now the FDA has added a new warning to its labeling about a risk of new-onset hypertension and worsening of preexisting hypertension associated with use of the drug. CGRP is a potent microvascular vasodilator; blocking or deleting it has produced hypertensive effects in animals.
Med Lett Drugs Ther. 2021 Apr 5;63(1621):56 | Show Full IntroductionHide Full Introduction